An Invitae-led retrospective study found almost a third of cancer patients who underwent germline genetic testing after tumor sequencing had pathogenic variants.
The society recommends routine use of multigene NGS for a handful of metastatic cancers, as well as in the context of clinical trials at academic centers.
